• Molecular NameEstazolam
  • SynonymNA
  • Weight294.745
  • Drugbank_IDDB01215
  • ACS_NO29975-16-4
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)2.14
  • pkaN/A
  • LogD (pH=7, predicted)2.12
  • Solubility (experiment)0.0015 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-4.54
  • LogSw (predicted, AB/LogsW2.0)0.03
  • Sw (mg/ml) (predicted, ACD/Labs)0.01
  • No.of HBond Donors0
  • No.of HBond Acceptors4
  • No.of Rotatable Bonds1
  • TPSA42.55
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA drug which is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability93.0
  • Protein binding93.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmExtensively metabolized in the liver. In vitro studies with human liver microsomes indicate that the biotransformation of estazolam to the major circulating metabolite 4-hydroxy-estazolam is mediated by cytochrome P450 3A (CYP3A).
  • Half life10-24 h
  • ExcretionRenal
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySymptoms of overdose include confusion, depressed breathing, drowsiness and eventually coma, lack of coordination, and slurred speech.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A